Lo-Zumandimine

Birth Control, Acne Vulgaris, Folate supplementation therapy + 9 more
Treatment
20 Active Studies for Lo-Zumandimine

What is Lo-Zumandimine

DrospirenoneThe Generic name of this drug
Treatment SummaryDrospirenone is a hormone used in combination with estrogen in birth control pills like Yaz and Estetrol. It can also be used to treat acne and PMDD. It has been linked to an increased risk of venous thromboembolism, but this has not been fully proven. The FDA states that the risk of thromboembolic events is lower than the risk during pregnancy or postpartum, so this should be taken into account when deciding whether to use this medication.
Yasminis the brand name
image of different drug pills on a surface
Lo-Zumandimine Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Yasmin
Drospirenone
2001
64

Effectiveness

How Lo-Zumandimine Affects PatientsDrospirenone prevents pregnancy by stopping the growth of eggs in the ovaries and preventing ovulation. It also has anti-androgen effects, which can improve acne and hirsutism. Taking drospirenone combined with ethinyl estradiol has been found to have positive effects on cholesterol levels. Additionally, due to its similarity to natural progesterone, it may cause fewer side effects related to progesterone than other contraceptive drugs. However, taking drospirenone can increase the risk of developing venous thromboembolism or other cardiovascular events, especially in those who are smokers or are 35 and older
How Lo-Zumandimine works in the bodyDrospirenone and ethinyl estradiol work together to prevent pregnancy. They do this by stopping the release of hormones that trigger ovulation. They also change the consistency of cervical mucus, making it harder for sperm to reach an egg. Drospirenone is related to a diuretic drug, which makes your body get rid of extra salt and water. It also works against androgens, which can lead to acne and excessive hair growth. Finally, it reduces swelling in sebaceous follicles, which helps to prevent acne.

When to interrupt dosage

The amount of Lo-Zumandimine is contingent upon the determined illness, including moderate to serious indications, Menopause and Post-Menarche. The dosage also shifts as indicated by the technique of administration (e.g. Tablet, film coated - Oral or Oral) mentioned in the table beneath.
Condition
Dosage
Administration
Birth Control
, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg
, Kit, Tablet, film coated - Oral, Tablet, film coated, Oral, Kit - Oral, Tablet, Tablet - Oral
moderate to severe symptoms
, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg
, Kit, Tablet, film coated - Oral, Tablet, film coated, Oral, Kit - Oral, Tablet, Tablet - Oral
N-Cadherins
, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg
, Kit, Tablet, film coated - Oral, Tablet, film coated, Oral, Kit - Oral, Tablet, Tablet - Oral
Hormonal Contraception
, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg
, Kit, Tablet, film coated - Oral, Tablet, film coated, Oral, Kit - Oral, Tablet, Tablet - Oral
Vasomotor System
, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg
, Kit, Tablet, film coated - Oral, Tablet, film coated, Oral, Kit - Oral, Tablet, Tablet - Oral
Acne Vulgaris
, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg
, Kit, Tablet, film coated - Oral, Tablet, film coated, Oral, Kit - Oral, Tablet, Tablet - Oral
Adherence to Oral Contraceptive Therapy
, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg
, Kit, Tablet, film coated - Oral, Tablet, film coated, Oral, Kit - Oral, Tablet, Tablet - Oral
Atrophic
, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg
, Kit, Tablet, film coated - Oral, Tablet, film coated, Oral, Kit - Oral, Tablet, Tablet - Oral
Post-Menarche
, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg
, Kit, Tablet, film coated - Oral, Tablet, film coated, Oral, Kit - Oral, Tablet, Tablet - Oral
Atrophy of vulva
, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg
, Kit, Tablet, film coated - Oral, Tablet, film coated, Oral, Kit - Oral, Tablet, Tablet - Oral
Folate supplementation therapy
, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg
, Kit, Tablet, film coated - Oral, Tablet, film coated, Oral, Kit - Oral, Tablet, Tablet - Oral
Hot flashes
, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg
, Kit, Tablet, film coated - Oral, Tablet, film coated, Oral, Kit - Oral, Tablet, Tablet - Oral

Warnings

Lo-Zumandimine Contraindications
Condition
Risk Level
Notes
Chronic Kidney Disease
Do Not Combine
Venous Thrombosis
Do Not Combine
Neoplasms, Hormone-Dependent
Do Not Combine
Migraine with Aura
Do Not Combine
Porphyrias
Do Not Combine
Breast
Do Not Combine
suspected pregnancy
Do Not Combine
Breast Milk Production
Do Not Combine
Metrorrhagia
Do Not Combine
Hypersensitivity
Do Not Combine
Liver Failure, Acute
Do Not Combine
Acute Kidney Injury
Do Not Combine
Deep Vein Thrombosis (DVT)
Do Not Combine
Vision Loss
Do Not Combine
Endometrial Hyperplasia
Do Not Combine
Tobacco Use
Do Not Combine
Liver Function Tests
Do Not Combine
Thrombophilia
Do Not Combine
Thromboembolism
Do Not Combine
high risk of arterial thrombotic disease
Do Not Combine
estrogen-dependent neoplasia
Do Not Combine
Liver Neoplasms
Do Not Combine
Adrenal Insufficiency
Do Not Combine
Thrombosis
Do Not Combine
Breast
Do Not Combine
estrogen-dependent neoplasia
Do Not Combine
There are 20 known major drug interactions with Lo-Zumandimine.
Common Lo-Zumandimine Drug Interactions
Drug Name
Risk Level
Description
Tranexamic acid
Major
Drospirenone may increase the thrombogenic activities of Tranexamic acid.
Acetohexamide
Minor
The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Drospirenone.
Agmatine
Minor
The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Agmatine.
Aliskiren
Minor
The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Aliskiren.
Anisodamine
Minor
The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Anisodamine.
Lo-Zumandimine Toxicity & Overdose RiskThe most toxic dose of drospirenone for rats is greater than 2000mg/kg. Signs of drospirenone overdose may include nausea, irregular bleeding, and disturbances in the levels of sodium and potassium in the blood. In cases of overdose, the levels of these substances should be monitored closely, as well as for signs of metabolic acidosis and high potassium levels.

Lo-Zumandimine Novel Uses: Which Conditions Have a Clinical Trial Featuring Lo-Zumandimine?

At present, 104 active studies are being conducted to evaluate the utility of Lo-Zumandimine for Acne Vulgaris, Post-Menarche and N-Cadherins.
Condition
Clinical Trials
Trial Phases
N-Cadherins
0 Actively Recruiting
moderate to severe symptoms
0 Actively Recruiting
Folate supplementation therapy
0 Actively Recruiting
Acne Vulgaris
0 Actively Recruiting
Atrophy of vulva
1 Actively Recruiting
Not Applicable
Hormonal Contraception
0 Actively Recruiting
Hot flashes
19 Actively Recruiting
Not Applicable, Phase 4, Phase 2, Early Phase 1, Phase 3
Post-Menarche
0 Actively Recruiting
Adherence to Oral Contraceptive Therapy
0 Actively Recruiting
Birth Control
22 Actively Recruiting
Not Applicable, Phase 3, Phase 4, Early Phase 1, Phase 2
Atrophic
4 Actively Recruiting
Phase 4, Not Applicable
Vasomotor System
0 Actively Recruiting

Patient Q&A Section about lo-zumandimine

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does Lo-Zumandimine have estrogen?

"Lo-Zumandimine is a combined oral contraceptive (COC) that contains the synthetic forms of the female hormones estrogen and progesterone. It is indicated for use by women to prevent pregnancy, to treat symptoms of premenstrual dysphoric disorder (PMDD), and to treat moderate acne in women who are at least 14 years old and have started having their period."

Answered by AI

What kind of birth control is Zumandimine?

"This medication is a combination of an estrogen and a progestin. This product is used to prevent pregnancy."

Answered by AI

Is Lo-Zumandimine the same as Yaz?

"This medication is used to prevent pregnancy. It may also be used to treat premenstrual dysphoric disorder (PMDD) or acne in women who are using birth control pills.

This medication is used to prevent pregnancy. It may also be used to treat premenstrual dysphoric disorder (PMDD) or acne in women who are using birth control pills."

Answered by AI

Is Lo-Zumandimine good for acne?

"The drug Lo-Zumandimine is indicated for the treatment of moderate acne in women 14 years of age or older, who do not have any known conditions that would make taking oral contraception unsafe, and who have started having their period."

Answered by AI

Clinical Trials for Lo-Zumandimine

Image of Erevna Innovations Inc. in Montreal, Canada.

Sculptra + Restylane for Post-Menopausal Skin Concerns

40 - 65
Female
Montreal, Canada
The post-menopausal state is marked by a sharp decline in estrogen, leading to significant structural and functional changes in the skin, including collagen loss, dryness, thinning, and reduced elasticity. To address these concerns, aesthetic injectables products such as Sculptra® Aesthetic (poly-L-lactic-acid \[PLLA- SCA\]) and Restylane Skinboosters®\[HASBV\] (small-particle hyaluronic acid - SP-HA) can be used. PLLA-SCA stimulates collagen production via cellular activation (biostimulator), gradually improving dermal structure. HASBV enhances hydration, elasticity, and skin texture when injected under the skin. Considering that hydration and laxity represent the primary aesthetic concerns in this patient population. Targeted treatment with SP-HA (HASBV) to improve hydration and PLLA-SCA to address laxity have been shown to produce significant clinical outcomes by directly addressing these key dermal deficiencies. This approach forms the basis of the current study.
Phase 4
Recruiting
Erevna Innovations Inc.Andreas Nikolis, MD, PhD
Have you considered Lo-Zumandimine clinical trials? We made a collection of clinical trials featuring Lo-Zumandimine, we think they might fit your search criteria.Go to Trials
Image of University of California, San Diego in La Jolla, United States.

Lidocaine for Pain Control in Birth Control

18 - 50
Female
La Jolla, CA
The goal of this research study is to learn more about how different uses of a numbing medication might affect pain levels while getting an IUD placed. The investigators are also studying participants opinions of their clinicians' empathy. The investigators are inviting patients who arrive at their clinic visit seeking an IUD. Usually, at University of California, San Diego (UCSD), for patients who have never delivered a baby, clinicians use a buffered paracervical block for before IUD placement. The purpose of this research study is to investigate whether a "buffered" (2 cc of sodium bicarbonate, 18 cc of 1% lidocaine) paracervical block (numbing medication given on both sides of the cervix) is effective in reducing pain during IUD placement in individuals with prior C-sections, the difference between buffered and unbuffered for nulliparous patients, and whether a medicated gel reduces pain with the paracervical block.
Recruiting
Paid Trial
University of California, San DiegoSheila K Mody, MD, MPH
Have you considered Lo-Zumandimine clinical trials? We made a collection of clinical trials featuring Lo-Zumandimine, we think they might fit your search criteria.Go to Trials
Image of Calabasas Pharmacy in Calabasas, United States.

Electronic Health Record Platform for Birth Control

18 - 51
Female
Calabasas, CA
Hormonal contraceptives are medications that require a prescription, traditionally from a physician or advanced practice provider. Over the past decade, pharmacists have gained the authority to prescribe contraceptives in many states, allowing patients to access these medications directly in pharmacies without first seeing another healthcare provider. The Pharmacist Resource to Implement Services as Modules (PRISM) is an Electronic Health Record platform designed to streamline workflows and provide clinical decision support, making it easier and safer to deliver clinical services in community pharmacies. This pilot study will evaluate patient-reported outcomes for women receiving contraceptive services from pharmacists using the PRISM platform at five community pharmacies across the United States over a 12-week period. The study will assess the quality of care, contraception continuation and failure rates, side effect rates, preventative healthcare utilization, and overall patient experience with pharmacy contraceptive services.
Waitlist Available
Has No Placebo
Calabasas Pharmacy (+4 Sites)OvaryIt, LLC
Image of Noll Laboratory in University Park, United States.

Estradiol and Elagolix for Menopause

42 - 64
Female
University Park, PA
The frequency and severity of heat waves has increased in the last decades. Older adults (over 65 years) have impaired responses to heat stress making them at increased risk for adverse events. Previous heat waves report that women over 65 experience worse health outcomes than any other age group and age matched men. Aging and reproductive hormones, specifically estrogen, independently alter responses to heat stress. However, the combined effects of low estrogen following menopause and aging on the response to heat stress are unknown. In this study, the investigators will identify the role of estrogen in pre and post menopausal women on thermoregulatory responses to heat stress.
Phase 4
Recruiting
Noll LaboratoryW. Larry Kenney, Ph.D.
Have you considered Lo-Zumandimine clinical trials? We made a collection of clinical trials featuring Lo-Zumandimine, we think they might fit your search criteria.Go to Trials